Copenhagen, Denmark; May 22, 2014 – Genmab A/S (OMX: GEN) announced today that data from two ongoing studies of daratumumab, in addition to pre-clinical data, will be presented at the 19th Congress of the European Hematology Association (EHA) in Milan Italy, June 12-15. Data from the Phase I/II study of daratumumab as a monotherapy to treat patients with relapsed or refractory multiple myeloma as well as results from the Phase I/II study of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma will be presented in poster sessions. These data are also being presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30 – June 3. The abstracts are available at the EHA website at www.ehaweb.org.
Help employers find you! Check out all the jobs and post your resume.
